Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144678 | 0.79 | PIK3CD (0.30) | — | |
| SCHEMBL10104251 | 0.76 | DRD4 (0.37) | DRD4DRD2PDE9A | |
| SCHEMBL23234657 | 0.76 | KDM4E (0.32) | — | |
| SCHEMBL4359161 | 0.76 | BPTF (0.34) | DRD4PDE9A | |
| SCHEMBL22363283 | 0.73 | DRD4 (0.37) | DRD4DRD2PDE9A | |
| SCHEMBL25581844 | 0.73 | DRD4 (0.35) | DRD4DRD2PDE9A | |
| SCHEMBL24504750 | 0.73 | DRD4 (0.35) | DRD4DRD2PDE9A | |
| SCHEMBL23399096 | 0.73 | DRD4 (0.35) | DRD4DRD2PDE9A | |
| SCHEMBL27440489 | 0.73 | DRD4 (0.35) | DRD4DRD2PDE9A | |
| SCHEMBL5021281 | 0.73 | CYP1A2 (0.33) | DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713319-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-25 | — | — | EP | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2024236528-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-11-21 | — | — | WO | disclosed |
| CN-115626923-B | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2015131005-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150246923-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-03 | — | — | US | disclosed |
| US-9012479-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2421537-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GlaxoSmithKline LLC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4359/4885ALOX15 3170/4885DRD4 4791/4885 |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | TSHR 1767/4885ALOX15 4606/4885DRD4 3653/4885 |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | TSHR 1767/4885ALOX15 4606/4885DRD4 3653/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4359/4885ALOX15 3170/4885DRD4 4791/4885 |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | TSHR 1767/4885ALOX15 4606/4885DRD4 3653/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TSHR 4359/4885ALOX15 3170/4885DRD4 4791/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4359/4885ALOX15 3170/4885DRD4 4791/4885 |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TSHR 4359/4885ALOX15 3170/4885DRD4 4791/4885 |
| US-20150246923-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | TSHR 1337/4885ALOX15 4413/4885DRD4 813/4885 |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | TSHR 1767/4885ALOX15 4606/4885DRD4 3653/4885 |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | TSHR 1767/4885ALOX15 4606/4885DRD4 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.